Global Clinical Stage Biotechnology 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03259068

Publication Date:

March 5, 2025

Pages:

116

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Clinical Stage Biotechnology market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Clinical Stage Biotechnology is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Clinical Stage Biotechnology is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Clinical Stage Biotechnology is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Clinical Stage Biotechnology players cover Minoryx, Inhibrx, NovaBiotics, RadioMedix, Artax Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淐linical Stage Biotechnology Industry Forecast鈥� looks at past sales and reviews total world Clinical Stage Biotechnology sales in 2024, providing a comprehensive analysis by region and market sector of projected Clinical Stage Biotechnology sales for 2025 through 2031. With Clinical Stage Biotechnology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Clinical Stage Biotechnology industry.
This Insight Report provides a comprehensive analysis of the global Clinical Stage Biotechnology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Clinical Stage Biotechnology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Clinical Stage Biotechnology market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Clinical Stage Biotechnology and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Clinical Stage Biotechnology.
This report presents a comprehensive overview, market shares, and growth opportunities of Clinical Stage Biotechnology market by product type, application, key players and key regions and countries.
Segmentation by Type:
Phase I
Phase II
Phase III
Segmentation by Application:
Bio-pharmaceuticals
Scientific Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Minoryx
Inhibrx
NovaBiotics
RadioMedix
Artax Biopharma
Ribon Therapeutics
Brickell Biotech
Coave Therapeutics
Edesa Biotech
CellCentric
LimmaTech Biologics AG
Adaptive Phage Therapeutics
Intra-ImmuSG

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Clinical Stage Biotechnology 麻豆原创 Size (2020-2031)
2.1.2 Clinical Stage Biotechnology 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Clinical Stage Biotechnology by Country/Region (2020, 2024 & 2031)
2.2 Clinical Stage Biotechnology Segment by Type
2.2.1 Phase I
2.2.2 Phase II
2.2.3 Phase III
2.3 Clinical Stage Biotechnology 麻豆原创 Size by Type
2.3.1 Clinical Stage Biotechnology 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Clinical Stage Biotechnology 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Clinical Stage Biotechnology Segment by Application
2.4.1 Bio-pharmaceuticals
2.4.2 Scientific Research
2.5 Clinical Stage Biotechnology 麻豆原创 Size by Application
2.5.1 Clinical Stage Biotechnology 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Clinical Stage Biotechnology 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Clinical Stage Biotechnology 麻豆原创 Size by Player
3.1 Clinical Stage Biotechnology 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Clinical Stage Biotechnology Revenue by Player (2020-2025)
3.1.2 Global Clinical Stage Biotechnology Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Clinical Stage Biotechnology Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Clinical Stage Biotechnology by Region
4.1 Clinical Stage Biotechnology 麻豆原创 Size by Region (2020-2025)
4.2 Global Clinical Stage Biotechnology Annual Revenue by Country/Region (2020-2025)
4.3 Americas Clinical Stage Biotechnology 麻豆原创 Size Growth (2020-2025)
4.4 APAC Clinical Stage Biotechnology 麻豆原创 Size Growth (2020-2025)
4.5 Europe Clinical Stage Biotechnology 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Clinical Stage Biotechnology 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Clinical Stage Biotechnology 麻豆原创 Size by Country (2020-2025)
5.2 Americas Clinical Stage Biotechnology 麻豆原创 Size by Type (2020-2025)
5.3 Americas Clinical Stage Biotechnology 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Clinical Stage Biotechnology 麻豆原创 Size by Region (2020-2025)
6.2 APAC Clinical Stage Biotechnology 麻豆原创 Size by Type (2020-2025)
6.3 APAC Clinical Stage Biotechnology 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Clinical Stage Biotechnology 麻豆原创 Size by Country (2020-2025)
7.2 Europe Clinical Stage Biotechnology 麻豆原创 Size by Type (2020-2025)
7.3 Europe Clinical Stage Biotechnology 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Clinical Stage Biotechnology by Region (2020-2025)
8.2 Middle East & Africa Clinical Stage Biotechnology 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Clinical Stage Biotechnology 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Clinical Stage Biotechnology 麻豆原创 Forecast
10.1 Global Clinical Stage Biotechnology Forecast by Region (2026-2031)
10.1.1 Global Clinical Stage Biotechnology Forecast by Region (2026-2031)
10.1.2 Americas Clinical Stage Biotechnology Forecast
10.1.3 APAC Clinical Stage Biotechnology Forecast
10.1.4 Europe Clinical Stage Biotechnology Forecast
10.1.5 Middle East & Africa Clinical Stage Biotechnology Forecast
10.2 Americas Clinical Stage Biotechnology Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Clinical Stage Biotechnology Forecast
10.2.2 Canada 麻豆原创 Clinical Stage Biotechnology Forecast
10.2.3 Mexico 麻豆原创 Clinical Stage Biotechnology Forecast
10.2.4 Brazil 麻豆原创 Clinical Stage Biotechnology Forecast
10.3 APAC Clinical Stage Biotechnology Forecast by Region (2026-2031)
10.3.1 China Clinical Stage Biotechnology 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Clinical Stage Biotechnology Forecast
10.3.3 Korea 麻豆原创 Clinical Stage Biotechnology Forecast
10.3.4 Southeast Asia 麻豆原创 Clinical Stage Biotechnology Forecast
10.3.5 India 麻豆原创 Clinical Stage Biotechnology Forecast
10.3.6 Australia 麻豆原创 Clinical Stage Biotechnology Forecast
10.4 Europe Clinical Stage Biotechnology Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Clinical Stage Biotechnology Forecast
10.4.2 France 麻豆原创 Clinical Stage Biotechnology Forecast
10.4.3 UK 麻豆原创 Clinical Stage Biotechnology Forecast
10.4.4 Italy 麻豆原创 Clinical Stage Biotechnology Forecast
10.4.5 Russia 麻豆原创 Clinical Stage Biotechnology Forecast
10.5 Middle East & Africa Clinical Stage Biotechnology Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Clinical Stage Biotechnology Forecast
10.5.2 South Africa 麻豆原创 Clinical Stage Biotechnology Forecast
10.5.3 Israel 麻豆原创 Clinical Stage Biotechnology Forecast
10.5.4 Turkey 麻豆原创 Clinical Stage Biotechnology Forecast
10.6 Global Clinical Stage Biotechnology Forecast by Type (2026-2031)
10.7 Global Clinical Stage Biotechnology Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Clinical Stage Biotechnology Forecast
11 Key Players Analysis
11.1 Minoryx
11.1.1 Minoryx Company Information
11.1.2 Minoryx Clinical Stage Biotechnology Product Offered
11.1.3 Minoryx Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Minoryx Main Business Overview
11.1.5 Minoryx Latest Developments
11.2 Inhibrx
11.2.1 Inhibrx Company Information
11.2.2 Inhibrx Clinical Stage Biotechnology Product Offered
11.2.3 Inhibrx Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Inhibrx Main Business Overview
11.2.5 Inhibrx Latest Developments
11.3 NovaBiotics
11.3.1 NovaBiotics Company Information
11.3.2 NovaBiotics Clinical Stage Biotechnology Product Offered
11.3.3 NovaBiotics Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 NovaBiotics Main Business Overview
11.3.5 NovaBiotics Latest Developments
11.4 RadioMedix
11.4.1 RadioMedix Company Information
11.4.2 RadioMedix Clinical Stage Biotechnology Product Offered
11.4.3 RadioMedix Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 RadioMedix Main Business Overview
11.4.5 RadioMedix Latest Developments
11.5 Artax Biopharma
11.5.1 Artax Biopharma Company Information
11.5.2 Artax Biopharma Clinical Stage Biotechnology Product Offered
11.5.3 Artax Biopharma Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Artax Biopharma Main Business Overview
11.5.5 Artax Biopharma Latest Developments
11.6 Ribon Therapeutics
11.6.1 Ribon Therapeutics Company Information
11.6.2 Ribon Therapeutics Clinical Stage Biotechnology Product Offered
11.6.3 Ribon Therapeutics Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Ribon Therapeutics Main Business Overview
11.6.5 Ribon Therapeutics Latest Developments
11.7 Brickell Biotech
11.7.1 Brickell Biotech Company Information
11.7.2 Brickell Biotech Clinical Stage Biotechnology Product Offered
11.7.3 Brickell Biotech Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Brickell Biotech Main Business Overview
11.7.5 Brickell Biotech Latest Developments
11.8 Coave Therapeutics
11.8.1 Coave Therapeutics Company Information
11.8.2 Coave Therapeutics Clinical Stage Biotechnology Product Offered
11.8.3 Coave Therapeutics Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Coave Therapeutics Main Business Overview
11.8.5 Coave Therapeutics Latest Developments
11.9 Edesa Biotech
11.9.1 Edesa Biotech Company Information
11.9.2 Edesa Biotech Clinical Stage Biotechnology Product Offered
11.9.3 Edesa Biotech Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Edesa Biotech Main Business Overview
11.9.5 Edesa Biotech Latest Developments
11.10 CellCentric
11.10.1 CellCentric Company Information
11.10.2 CellCentric Clinical Stage Biotechnology Product Offered
11.10.3 CellCentric Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 CellCentric Main Business Overview
11.10.5 CellCentric Latest Developments
11.11 LimmaTech Biologics AG
11.11.1 LimmaTech Biologics AG Company Information
11.11.2 LimmaTech Biologics AG Clinical Stage Biotechnology Product Offered
11.11.3 LimmaTech Biologics AG Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 LimmaTech Biologics AG Main Business Overview
11.11.5 LimmaTech Biologics AG Latest Developments
11.12 Adaptive Phage Therapeutics
11.12.1 Adaptive Phage Therapeutics Company Information
11.12.2 Adaptive Phage Therapeutics Clinical Stage Biotechnology Product Offered
11.12.3 Adaptive Phage Therapeutics Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Adaptive Phage Therapeutics Main Business Overview
11.12.5 Adaptive Phage Therapeutics Latest Developments
11.13 Intra-ImmuSG
11.13.1 Intra-ImmuSG Company Information
11.13.2 Intra-ImmuSG Clinical Stage Biotechnology Product Offered
11.13.3 Intra-ImmuSG Clinical Stage Biotechnology Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Intra-ImmuSG Main Business Overview
11.13.5 Intra-ImmuSG Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.